Share / Export Citation / Email / Print / Text size:

Postępy Mikrobiologii - Advancements of Microbiology

Polish Society of Microbiologists

Subject: Microbiology


ISSN: 0079-4252
eISSN: 2545-3149





Volume / Issue / page

Related articles

VOLUME 57 , ISSUE 2 (September 2018) > List of articles


Anna Żuk-Wasek / Natalia Żeber / Grażyna Młynarczyk / Maciej Przybylski * / Tomasz Dzieciątkowski

Keywords : gammaherpesviruses, HHV-4, HHV-8, immune deficiency, immunosuppression

Citation Information : Postępy Mikrobiologii - Advancements of Microbiology. Volume 57, Issue 2, Pages 145-155, DOI:

License : (CC BY-NC-ND 4.0)

Published Online: 23-May-2019



Human herpes virus type 4 (HHV-4), commonly known as Epstein-Barr virus (EBV), and human herpes virus type 8 (HHV-8) are members of Gammaherpesvirinae subfamily. They both develop latent infections in B lymphocytes. Infection with these viruses in immunocompetent patients is usually mild and self-limiting, but it can have more severe course in immunocompromised individuals. Failure of the immune system often leads to oncogenesis related to gammaherpetic infection. Thus, immunocompromised patients are far more likely to develop proliferative diseases caused by EBV or HHV-8. This problem also applies to HIV-positive individuals co-infected with EBV or HHV-8. Gammaherpesviruses can also be the cause of post-transplantation issues in patients on immunosuppressive drugs and EBV is known to induce severe clinical syndromes in people with specific genetic disorders. Presented article summarizes epidemiology, pathogenesis, clinical syndromes and treatment of EBV and HHV-8 in individuals with immunological disorders.

Content not available PDF Share



1. Ablashi D.V., Chatlynne L.G., Whitman J.E. Jr, Cesarman E.: Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin. Microbiol. Rev. 15, 439–464 (2002)

2. Achenbach C.J., Harrington R.D., Dhanireddy S., Crane H.M., Casper C., Kitahata M.M.: Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin. Infect. Dis. 54, 424–433 (2012)

3. Adamczyk K., Byczkowska K., Kowalska-Piaskowska A., Mozer-Lisewska I.: Zakażenia wywołane przez wirusy z rodziny Herpesviridae u osób HIV dodatnich. Now. Lek. 79, 474–478 (2010)

4. Andersson J.: Epstein-Barr virus and Hodgkin’s lymphoma. Herpes, 13, 12–16 (2006)

5. Aozasa K., Zaki MA.: Epidemiology and pathogenesis of nasal NK/T-cell lymphoma: a mini-review. ScientificWorld Journal. 11, 422–428 (2011)

6. Bornkamm GW.: Epstein-Barr virus and the pathogenesis of Burkitt’s lymphoma: more questions than answers. Int. J. Cancer. 124, 1745–1755 (2009)

7. Bower M., Nelson M., Young A.M., Thirlwell C., Newsom-Davis T., Mandalia S., Dhillon T., Holmes P., Gazzard B.G., Stebbing J.: Immunereconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J. Clin. Oncol. 23, 5224–5228 (2005)

8. Braun-Falco O., Plewig G., Wolff H., Burgdorf W. (red.). Dermatology. Wyd. 2. Springer Verlag, Berlin-Heidelberg, 2000, s. 1486–1488

9. Braz-Silva P.H., de Rezende N.P., Ortega K.L., de Macedo Santos R.T., de Magalhães M.H.: Detection of the Epstein-Barr virus (EBV) by in situ hybridization as definitive diagnosis of hairy leukoplakia. Head Neck Pathol. 2, 19–24 (2008)

10. Brinkmann M.M., Pietrek M., Dittrich-Breiholz O., Kracht M., Schulz T.F.: Modulation of host gene expression by the K15 protein of kaposi’s sarcoma-associated herpesvirus. J. Virol. 81, 42–58 (2007)

11. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S.. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117, 5019–5032 (2011)

12. Carbone A., Gloghini A.: AIDS-related lymphomas: from pathogenesis to pathology. Br. J. Haematol. 130, 662–670 (2005)

13. Carbone A., Gloghini A., Caruso A., De Paoli P., Dolcetti R.: The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. Int. J. Cancer. 140, 1233–1245 (2017)

14. Cattani P., Cerimele F., Porta D., Graffeo R., Ranno S., Marchetti S., Ricci R., Capodicasa N., Fuga L., Amico R., Cherchi G., Gazzilli M., Zanetti S., Fadda G.: Age-specific seroprevalence of human herpesvirus 8 in Mediterranean regions. Clin. Microbiol. Infect. 9, 274–279 (2003)

15. Cesarman E., Chang Y., Moore P.S., Said J.W., Knowles DM.: Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186–1191 (1995)

16. Cesarman E., Mesri E.A.: Virus-associated lymphomas. Curr. Opin. Oncol. 11, 322–332 (1999)

17. Cesarman E.: Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 305, 163–174 (2011)

18. Cesarman E.: Gammaherpesviruses and lymphoproliferative disorders. Annu. Rev. Pathol. 9, 349–372 (2014)

19. Chaigne-Delalande B., Lenardo M.J. i wsp: Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science, 341, 186–191 (2013)

20. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles DM., Moore P.S.: Identification of herpesvirus-like DNA sequence in AIDS-associated KS. Science, 266, 1865–1869 (1994)

21. Clavies A., Tiemann M., Wagner H-J., Dreger P., Suttorp M.: Epstein-Barr virus-associated post-transplant lymphoprolife-rative disease after bone marrow transplantation mimicking graft-versus-host disease. Pediatr. Transplant. 4, 151–155 (2000)

22. Connick E., Kane M.A., White I.E., Ryder J., Campbell T.B.: Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin. Infect. Dis. 39, 1852–1855 (2004)

23. Cote TR, Manns A, Hardy CR i wsp.: Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J. Natl. Cancer Inst. 88, 675–679 (1996)

24. Crane G.M., Ambinder R.F., Shirley C.M., Fishman E.K., Kasamon Y.L., Taube J.M., Borowitz M.J., Duffield A.S.: HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma. Am. J. Surg. Pathol. 38, 426–432 (2014)

25. Davi F., Raphaël M. i wsp.: Burkitt-like lymphomas in AIDS patients: Characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin’s lymphomas. Burkitt’s Lymphoma Study Group. J. Clin. Oncol. 16, 3788–3795 (1998)

26. De Paoli P., Carbone A.: Kaposi’s Sarcoma Herpesvirus: twenty years after its discovery. Eur. Rev. Med. Pharmacol. Sci. 20, 1288–1294 (2016)

27. Dow D.E., Cunningham C.K., Buchanan A.M.: A Review of human herpesvirus 8, the Kaposi’s sarcoma-associated herpesvirus, in the pediatric population. J. Pediatric. Infect. Dis. Soc. 3, 66–76 (2014)

28. Dupin N., Escande J.P. i wsp.: The influence of highly active antiretroviral therapy on AIDS-associated Kaposi’s sarcoma. Br. J. Dermatol. 140, 875–881 (1999)

29. Durandy A., Sutton L., Bordigoni P., Garnier J., Bidois J., Deist F., Blanche S., Fischer A.: Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood, 92, 3137–3147 (1998)

30. Ebell M.H.: Epstein-Barr virus infectious mononucleosis. Am. Fam. Physician. 70, 1279–1287 (2004)

31. Ensoli B., Barillari G., Salahuddin S.Z.: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients. Nature, 345, 84–86 (1990)

32. Emuss V., Lagos D., Pizzey A., Gratrix F., Henderson S.R., Boshoff C.: KSHV manipulates notch signaling by DLL4 and JAG1 to alter cell cycle genes in lymphatic endothelia. PLoS Pathog. 5, e100016 (2009)

33. Epstein M.A., Barr Y.M., Achong B.G.: A second virus-carrying tissue culture strain (EB2) of lymphoblasts from Burkitt’s lymphoma. Pathol. Biol. 12, 1233–1234 (1964)

34. Epstein M.A., Henle G., Achong B.G., Barr Y.M.: Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt’s lymphoma. J. Exp. Med. 121, 761–770 (1965)

35. Filipovich A.H., Zhang K., Snow A.L., Marsh R.A.: X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood, 116, 3398–3408 (2010)

36. Fujii T., Taguchi H., Katano H., Mori S., Nakamura T., Nojiri N., Nakajima K., Tadokoro K., Juji T., Iwamoto A.: Seroprevalence of human herpesvirus 8 in human immunodeficiency virus 1-positive and human immunodeficiency virus 1-negative populations in Japan. J. Med. Virol. 57, 159–162 (1999)

37. Geng L., Wang X.: Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. Int. J. Clin. Exp. Med. 8,14656–14671 (2015)

38. Ghosh S., Bienemann K., Boztug K., Borkhardt A.: Interleukin-2-inducible T-cell kinase (ITK) deficiency – clinical and molecular aspects. J. Clin. Immunol. 34, 892–899 (2014)

39. Görzer I., Niesters H.G., Cornelissen J.J., Puchhammer-Stöckl E.: Characterization of Epstein-Barr virus Type I variants based on linked polymorphism among EBNA3A, -3B, and -3C genes. Virus Res. 118, 105–114 (2006)

40. Gramolelli S., Schulz TF.: The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma. J. Pathol. 235, 368–380 (2015)

41. Grulich A.E., Vajdic C.M.: The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin. Oncol. 42, 247–257 (2015)

42. Hardie DR.: Human gamma-herpesviruses: a review of 2 divergent paths to oncogenesis. Transfus. Apher. Sci. 42, 177–183 (2014)

43. zur Hausen H.: Epstein-Barr virus. (w) Infections Causing Human Cancer. Wiley-VCH Verlag, Weinhem, 2006, s. 65–95

44. Hengge U., Ruzicka T., Tyring S.K., Stuschke M., Roggendorf M., Schwartz R.A., Seeber S.: Update on Kaposi’s sarcoma and other HHV-8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations and therapy. Lancet Infect. Dis. 2, 281–292 (2002)

45. Henke-Gendo C., Viejo-Borbolla A., Schulz T.F.: Kaposi’s sarkoma-associated herpesvirus (Human herpesvirus 8) (w) Principles and practice of clinical virology, red. A.J. Zuckerman, J.E. Banatvala, B.D. Schoub, P.D. Griffiths, P. Mortimer, Willey-Blackwell, Oxford, 2009, s. 245–261

46. Heslop HE.: How I treat EBV lymphoproliferation. Blood, 114, 4002–4008 (2009)

47. Hladik W., Pellett P.E., Hancock J., Downing R., Gao H., Packel L., Mimbe D., Nzaro E., Mermin J.: Association between transfusion with human herpesvirus 8 antibody-positive blood and subsequent mortality. J. Infect. Dis. 1206, 1497–1503 (2012)

48. Jędrzejczak W.W.: Limfohistiocytoza hemofagocytarna – rzadko rozpoznawany uleczalny stan bezpośredniego zagrożenia życia występujący również u dorosłych. Acta Haematol. Pol. 38, 515–526 (2008)

49. Kalinova L., Indrakova J., Bachleda P.: Post-transplant lymphoproliferative disorder. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 153, 251–257 (2009)

50. Karst J., Konopka L.: Poprzeszczepowa choroba limfoproliferacyjna. Onkol. Pol. 8, 209–216 (2005)

51. Kieff E., Rickinson A.B.: Epstein-Barr virus and its replication. (w) Fields Virology, wyd. 4, red. Fields B.N., Knipe D.M., Howley P. Philadelphia, PA: Lippincott Williams & Wilkins, 2001, s. 2511–2575

52. Kim H.J., Huh J. i in.: Hematopathology Study Group of the Korean Society of Pathologists. Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification. J. Pathol. Transl. Med. 51, 352–358 (2017)

53. Klein G.: Perspectives in studies of human tumor viruses. Front. Biosci. 7, 268–274 (2002)

54. Klepfish A., Zuckermann B., Schattner A.: Primary effusion lymphoma in the absence of HIV infection – clinical presentation and management. QJM. 108, 481–488 (2015)

55. Kleynberg R.L., Schiller G.J.: Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin. Adv. Hematol. Oncol. 10, 726–732 (2012)

56. Knowles D.M., Inghirami G., Ubriaco A., Dalla-Favera R.: Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood. 73, 792–799 (1989)

57. Kotlarek-Haus S., Haus O.: Chłoniaki u osób zakażonych HIV. Acta. Haematol. Pol. 31, 249–258 (2000)

58. Larocca L.M., Gaidano G., i wsp.: The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 92, 1011–1019 (1998)

59. Levine A.M., Tulpule A.: Clinical aspects and management of AIDS-related Kaposi’s sarcoma. Eur. J. Cancer. 37, 1288–1295 (2001)

60. Li F.Y., Chaigne-Delalande B., Kanellopoulou C., Davis J.C., Matthews H.F., Douek D.C., Cohen J.I., Uzel G., Su H.C., Lenardo M.J.: Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature, 475, 471–476 (2011)

61. Liu M., Liu B., Liu B., Wang Q., Ding L., Xia C., Dong L.: Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases. Oncol. Rep. 33, 1615–1620 (2015)

62. Luppi M., Barozzi P., Schulz T.F., Setti G., Staskus K., Trovato R., Narni F., Donelli A., Maiorana A., Marasca R., Sandrini S., Torelli G.: Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N. Engl. J. Med. 343, 1378–1385 (2000)

63. Machaczka M.: Limfohistiocytoza hemofagocytarna – współczesny problem medyczny. Pol. Merk. Lek. 187, 59–63 (2012)

64. Machowicz R., Drozd-Sokołowska J., Zduńczyk D., Górnicka B., Boguradzki P., Jędrzejczak W.: Limfohistiocytoza hemofagocytarna (HLH) indukowana przez chłoniaka – opis przypadku. OncoReview, 1, 304–307 (2011)

65. Marsh R.A., Madden L., Kitchen B.J., Mody R., McClimon B., Jordan M.B., Bleesing J.J., Zhang K., Filipovich A.H.: XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood, 116, 1079–1082 (2010)

66. Martin D., Galisteo R., Molinolo A.A., Wetzker R., Hirsch E., Gutkind J.S.: PI3Kgamma mediates kaposi’s sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell, 19, 805–813 (2011)

67. Mckee P.H., Calonje E., Granter S.R.: Pathology of the skin with clinical correlations. Elsevier Mosby, London, 2006, s. 1830–1836.

68. Minhas V., Wood C.: Epidemiology and transmission of Kaposi’s sarcoma-associated herpesvirus. Viruses. 6, 4178–94 (2014)

69. Mularoni A., Conaldi P.G. i wsp.: Successful Treatment of Kaposi Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome After Kidney-Liver Transplant: Correlations with the Human Herpesvirus 8 miRNome and Specific T Cell Response. Am. J. Transplant. doi: 10.1111/ajt.14346 (2017)

70. Münz C., Moormann A.: Immune escape by Epstein-Barr virus associated malignancies. Semin. Cancer. Biol. 18, 381–387 (2008)

71. Mutlu A.D., Mesri E.A. i wsp.: In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: A cell and animal model of virally induced kaposi’s sarcoma. Cancer Cell, 11, 245–258 (2007)

72. Neparidze N., Lacy J.: Malignancies associated with Epstein-Barr virus: pathobiology, clinical features, and evolving treatments. Clin. Adv. Hematol. Oncol. 12, 358–371 (2014)

73. Newlon J.L., Couch M., Brennan J.: Castleman’s disease: three case reports and a review of the literature. Ear Nose Throat J. 86, 414–418 (2007)

74. Oksenhendler E., Cazals-Hatem D., Schulz T.F., Barateau V., Grollet L., Sheldon J., Clauvel J.P., Sigaux F., Agbalika F.: Transient angiolymphoid hyperplasia and Kaposi’s sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection. N. Engl. J. Med. 338, 1585–1590 (1998)

75. Palac-Siczek M., Pierniczka-Załęska M., Borowska K.: Ograniczona choroba Castlemana o łagodnym przebiegu klinicznym – opis przypadku. Otolaryngol. Pol. 65, 108–111 (2011)

76. Pierangeli A., Antonelli G., Gentile G.: Immunodeficiency-associated viral oncogenesis. Clin Microbiol Infect. 21, 975–983 (2015)

77. Polizzotto M.N., Uldrick T.S., Hu D., Yarchoan R.: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome. Front. Microbiol. 3, 73 (2012)

78. Przybylski M., Dzieciatkowski T., Zduńczyk D., Jędrzejczak W.W., Luczak M.: Microbiological findings and treatment of EBV-associated hemophagocytic lymphohistiocytosis: a case report. Arch. Immunol. Ther. Exp. (Warsz). 58, 247–252 (2010)

79. Purtilo D.T., Cassel C.K., Yang J.P.S., Harper L.: X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet. 1, 935–940 (1975)

80. Purushothaman P., Dabral P., Gupta N., Sarkar R., Verma S.C.: KSHV genome replication and maintenance. Front. Microbiol. 7, 54 (2016)

81. Ravell J., Chaigne-Delalande B., Lenardo M.: X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia disease: a combined immune deficiency with magnesium defect. Curr. Opin. Pediatr. 26, 713–719 (2014)

82. Reddy N., Rezvani K., Barrett A.J., Savani BN.: Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol. Blood Marrow Transplant. 17, 591–597 (2011)

83. Lieberman P., Hu J., Renne R.: Gammaherpesvirus maintenance and replication during latency (w) Human Herpesviruses, Biology, Therapy and Immunoprophylaxis, red. Arvin A., Campadelli-Fiume G., Mocarski E., Moore P.S., Roizman B., Whitley R., Yamanishi K., Cambridge University Press, Cambridge, 2007, s. 379–403

84. Ruiz-Cordero R.R., Lewis J., Blieden C., Campuzano-Zuluaga G., Hernandez J., Lossos I.S., Ikpatt F., Chapman J.R., Vega F.: Unusual immunophenotypic variant of large B-cell lymphoma associated with HHV-8 and EBV in an HIV positive patient. Human Pathol.: Case Reports. 2, 49–54 (2015)

85. Sarmati L.: HHV-8 infection in African children. Herpes, 11, 2–8 (2004)

86. Schulz T.: The pleiotropic effects of Kaposi’s sarcoma herpesvirus. J. Path. 208, 187–198 (2006)

87. Schwartzberg P.L., Mueller K.L., Qi H., Cannons J.L.: SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat. Rev. Immunol., 9, 39–46 (2009)

88. Shu C.H., Chang Y.S., Liang C.L., Liu S.T., Lin C.Z., Chang P.: Distribution of type A and type B EBV in normal individuals and patients with head and neck carcinomas in Taiwan. J. Virol. Methods. 38, 123–130 (1992)

89. da Silva S.R., de Oliveira D.E.: HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett. 305, 175–185 (2011)

90. Simon K., Knysz B., Szybejko-Machaj G., Gładysz A: Mięsak Kaposiego u pacjentów z nabytym zespołem upośledzenia odporności (AIDS) — obserwacje własne. Współcz. Onkol. 1, 21–24 (2000)

91. Sodhi A., Montaner S., Patel V., Gomez-Roman J.J., Li Y., Sausville E.A., Sawai E.T., Gutkind J.S.: AKT plays a central role in sarcomagenesis induced by kaposi’s sarcoma herpesvirus-encoded g protein-coupled receptor. Proc. Natl. Acad. Sci. USA, 101, 4821–4826 (2004)

92. Soumerai J.D., Sohani A.R., Abramson J.S.: Diagnosis and management of Castleman disease. Cancer Control. 21, 266–278 (2014)

93. Stojanova J., Caillard S., Rousseau A., Marquet P.: Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. Pharmacol. Res. 63, 1–7 (2011)

94. Sumazaki R., Kanegane H., Osaki M., Fukushima T., Tsuchida M., Matsukura H., Shinozaki K., Kimura H., Matsui A., Miyawaki T.: SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. Blood, 98, 1268–1270 (2001)

95. Tappero J.W., Conant M.A., Wolf S.F., Berger T.G.: Kaposi’s sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J. Am. Acad. Dermatol. 28, 371–395 (1993)

96. Thompson MP., Kurzrock R.: Epstein-Barr virus and cancer. Clin. Cancer Res. 10, 803–821 (2004)

97. Thorley-Lawson D.A., Gross A.: Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350, 1328–1337 (2004)

98. Tserenpuntsag B., Kołacińska A., Jabłonowska E.: Nowotwory związane z AIDS w erze skojarzonego leczenia antyretrowirusowego (HAART). Przegl. Epidemiol. 61, 529–534 (2007)

99. Uldrick T.S., Whitby D.: Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. Cancer Lett. 305, 150–162 (2011)

100. Vereide D., Sugden B.: Proof for EBV’s sustaining role in Burkitt’s lymphomas. Semin. Cancer Biol. 19, 389–393 (2009)

101. Viejo-Borbolla A., Schulz T.F.: Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev. 5, 222–229 (2003)

102. Weiss L.M., Epstein-Barr virus and Hodgkin’s disease. Curr. Oncol. Rep. 2, 199–204 (2000)

103. Zhang K., Wakefield E., Marsh R.: Lymphoproliferative Disease, X-Linked. 27.02.2004 [aktualizacja 30.06.2016]. (w) Pagon R.A., Adam M.P., Ardinger H.H. i in. (red.): Gene Reviews® [Internet], University of Washington, Seattle,